Soleno Therapeutics (SLNO) Receivables (2013 - 2026)

Soleno Therapeutics' (SLNO) quarterly Receivables came in at $47.1 million in Q1 2026, up 67.11% on a QoQ basis from $28.2 million in Q4 2025.

Soleno Therapeutics (SLNO) Receivables (2013 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 8 years of Receivables data on file, last reported at $47.1 million in Q1 2026.

On a quarterly basis, Receivables changed N/A year-over-year to $47.1 million in Q1 2026; TTM through Mar 2026 was $47.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $28.2 million, changed N/A from the prior year.
Receivables for Q1 2026 stood at $47.1 million, up from $28.2 million in the prior quarter.
Over the last five years, Receivables for SLNO reached as high as $47.1 million in Q1 2026 and fell as low as $24.6 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	4.97 Mn
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	938.02 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Soleno Therapeutics	874.25 Mn	618.67 Mn	93.41 Mn	47.14 Mn

Download Data